Dear Einstein Community:

At last week’s senate meeting, Ed Burns mentioned that an announcement would be forthcoming concerning leadership of our Ruth L. and David S. Gottesman Institute for Stem Cell Biology and Regenerative Medicine Research. At this time, I’m pleased to share with you that Ulrich Steidl, M.D., Ph.D., professor of cell biology and of medicine, will serve as the institute’s interim director.

Uli has graciously agreed to take on this role temporarily in the wake of the unexpected loss of Paul Frenette, M.D., who died from a rare disease in July of this year. He is well suited for this position, given his expertise in cancer stem cells, proven leadership skills, and the high level of respect he holds among his colleagues at Einstein and throughout the world. We thank Uli for undertaking this new role to support the productivity and collaborative efforts of our institute researchers and staff.

Uli takes on this position in addition to co-directing the Blood Cancer Institute in our cancer center and directing our Stem Cell Isolation & Xenotransplantation Facility. He also is associate director for basic science in the Albert Einstein Cancer Center, holds the Rose C. Falkenstein Chair in Cancer Research, and is the Diane and Arthur B. Belfer Faculty Scholar in Cancer Research.

Please join me in congratulating Uli on this appointment.

Sincerely,

Gordon F. Tomaselli, M.D.
The Marilyn and Stanley M. Katz Dean
Albert Einstein College of Medicine
Executive Vice President and Chief Academic Officer
Montefiore Medicine